Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis

To discover novel biomarkers of psoriasis, a target‐specific antibody array screening of serum samples from psoriasis patients was initially performed. The results revealed that vascular endothelial growth factor receptor 3 ( VEGFR ‐3) was significantly elevated in the sera of psoriasis patients, compared to healthy controls. Next, ELISA validation studies in a larger cohort of psoriasis patients (N = 73) were conducted, which confirmed that serum VEGFR ‐3 was indeed significantly increased in patients with psoriasis compared to healthy controls ( P  < 0.001). Furthermore, receiver operating characteristic curve analysis demonstrated that serum VEGFR ‐3 exhibited potential in distinguishing healthy controls from psoriasis patients: area under the curve = 0.85, P  < 0.001. In addition, serum levels of VEGFR ‐3 were correlated with Psoriasis Area Severity Index scores ( R  = 0.32, P  = 0.008) in psoriasis patients. Interestingly, serum VEGFR ‐3 levels were significantly elevated in psoriatic arthritis compared to non‐psoriatic arthritis ( P  = 0.026). A pilot longitudinal study demonstrated that serum levels of VEGFR ‐3 could reflect disease progression in psoriasis. Collectively, serum VEGFR ‐3 may have a clinical value in monitoring disease activity of psoriasis.